Data Featured in PLOS ONE Contribute to MacroGenics' Platform to Identify Monoclonal Antibodies that Target Cancer Stem Cells

Results Support Clinical Development of MGD006 in Hematologic Malignancies

ROCKVILLE, Md. , Nov. 12, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate

ROCKVILLE, Md. , Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that

Selection of a Pre-Clinical Development Candidate Triggers a $5 Million Milestone Payment

ROCKVILLE, Md. , Nov. 5, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, November 12, 2013 , the Company will release its financial results for the third quarter ended September 30, 2013 . The Company's management team will host a conference call discussing

ROCKVILLE, Md. , Oct. 16, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced the closing of its initial public offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to

MacroGenics Announces Pricing of Initial Public Offering ROCKVILLE, Md., October 9, 2013 - MacroGenics, Inc., today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $16.00 per share.

Dr. David C. Stump to join company’s Board of Directors

Study to examine safety, pharmacokinetics and
anti-tumor effect of potential first-in-class B7-H3 targeted cancer immunotherapy

MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development ROCKVILLE, Md., August 12, 2013 — MacroGenics, Inc. today announced that it has appointed Jon Wigginton, M.D., as Senior Vice President, Clinical Development. Dr.

MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer ROCKVILLE, Md., June 3, 2013—MacroGenics, Inc.

MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer ROCKVILLE, Maryland - May 21, 2013/PRNewswire/ - MacroGenics, Inc.

<ul>
<li>Based on MacroGenics&#8217; proprietary DART technology for generating bi-specific antibodies</li>
<li>Gilead receives rights to four pre-clinical programs</li>
<li>MacroGenics retains development and commercial rights to one of the programs in major markets outside North America and the European Union</li></ul>

<ul>
<li>Includes three novel pre-clinical programs for the treatment of solid and liquid tumors</li>
<li>Based on MacroGenics' proprietary DART technology for generating bi-specific antibodies that redirect the body's own immune system to kill cancer cells</li>
<li>MacroGenics retains full rights to each program in North America, Japan, Korea and India</li>
<li>Servier has the option to obtain exclusive license to develop and commercialize each program in the rest of the world</li></ul>

ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases Los Angeles, CA and Rockville, MD – September 5, 2012. ImaginAb, Inc.

ROCKVILLE , Maryland , December 20, 2011- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.   The milestone payment was triggered as part of an agreement

<ul>
<li>MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide variety of solid tumors</li>
<li>MacroGenics retains full program rights in North America, Japan, Korea and India</li>
<li>Servier has an option to obtain an exclusive license to develop and commercialize MGA271 in the rest of the world</li></ul>

ROCKVILLE , MD. , June 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protégé, a Phase 3 clinical study of teplizumab

ROCKVILLE, MD., June 23 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protégé, the Company’s Phase 3 clinical study of teplizumab in type

ROCKVILLE , MD. , April 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent

ROCKVILLE , MD. , January 6 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical

Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics INGELHEIM, Germany and ROCKVILLE, MD, USA, October 26, 2010 -- Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global

ROCKVILLE, MD, October 26, 2010 -- MacroGenics, Inc, a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting

MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint ROCKVILLE, Md., INDIANAPOLIS, Ind. – Oct. 20, 2010 – MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protégé Data Monitoring Committee (DMC), composed of